Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,016 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group].
Abe R, Tominaga T, Nomizu T, Nomura Y, Takashima S, Koyama H, Sano M, Tohge T, Ueo H, Ikeda S, Ohashi Y; CGS20267 Study Group. Abe R, et al. Among authors: tominaga t. Gan To Kagaku Ryoho. 2002 May;29(5):729-40. Gan To Kagaku Ryoho. 2002. PMID: 12040677 Clinical Trial. Japanese.
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group].
Kimijima I, Tominaga T, Nomizu T, Nomura Y, Takashima S, Koyama H, Sano M, Tohge T, Ueo H, Ikeda S, Ohashi Y; CGS20267 Study Group. Kimijima I, et al. Among authors: tominaga t. Gan To Kagaku Ryoho. 2002 May;29(5):741-9. Gan To Kagaku Ryoho. 2002. PMID: 12040678 Clinical Trial. Japanese.
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O. Tominaga T, et al. J Clin Oncol. 2003 Mar 15;21(6):991-8. doi: 10.1200/JCO.2003.06.014. J Clin Oncol. 2003. PMID: 12637462 Clinical Trial.
[Late phase II clinical study of KW-2307 in advanced/recurrent breast cancer patients (II)].
Tominaga T, Nomura Y, Horikoshi N, Takashima S, Kimura M, Koyama H, Kikkawa N, Toge T, Mitsuyama S, Morimoto T, Enomoto K, Wada T, Kimishima I, Niitani H; KW-2307 Cooperative Study Group (Breast Cancer Section). Tominaga T, et al. Gan To Kagaku Ryoho. 2005 Jul;32(7):983-90. Gan To Kagaku Ryoho. 2005. PMID: 16044960 Clinical Trial. Japanese.
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y; Adjuvant CEF Research Group for Breast Cancer. Kimura M, et al. Among authors: tominaga t. Breast Cancer. 2010 Jul;17(3):190-8. doi: 10.1007/s12282-009-0132-x. Epub 2009 Jul 3. Breast Cancer. 2010. PMID: 19575284 Clinical Trial.
The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial.
Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M, Enomoto K, Watanabe H, Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T, Monden Y, Hattori T, Nomura Y, Sugimachi K, Hirata K, Nakazato H, Miura S, Morimoto T, Asaishi K, Kimijima I, Ota J, Sonoo H, Yamaguchi S; 5'-BC Study Group (5'-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group). Tominaga T, et al. Int J Oncol. 2002 Mar;20(3):517-25. Int J Oncol. 2002. PMID: 11836563 Clinical Trial.
2,016 results